Andrew Hendifar, M.d.

Andrew Hendifar, M.D., is the medical oncology lead for the Gastrointestinal Disease Research Group at Cedars-Sinai and co-director of Pancreas Oncology. He and his colleagues from Surgery, Gastroenterology, Radiation Oncology and Radiology have formed multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors.

Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine and pancreatic cancer. He also conducts research involving cachexia in cancer patients, and has developed a treatment protocol in pancreatic cancer cachexia. Dr. Hendifar is the primary investigator for several trials in the treatment of pancreatic cancer, colon cancer, and neuroendocrine tumors.

Dr. Hendifar's work has been published in prestigious journals, including the Lancet, Cancer, Journal of Clinical Oncology, and Clinical Cancer Research. Dr. Hendifar has displayed deep subject-matter knowledge in presentations for organizations such as the National Institutes of Health and the American Society of Clinical Oncology. His patient care has also been recognized, as he was named a "Top Doctor" in 2010 and has been listed a "Super Doctor” since 2013.